The initiation and progression of human cancer is a multistep process that must involve genetic alterations of critical genes controlling the destiny of defined cell lineages with regard to cellular proliferation, differentiation, or death. Elucidation of the genetic mechanisms underlying these growth control processes is crucial to understanding the origins of the malignant state. Prostate cancer is the most common cancer in men and, with rising incidence, is the second leading cause of male cancer deaths in the United States (1, 2) . The search for specific genetic changes associated with prostate cancer has failed to uncover a single high-frequency event (with the exception of overproduction of prostate-specific antigen).
Cytogenetic and loss of heterozygosity studies, however, have pointed to several regions of the human genome that could contain tumor suppressor genes involved in the etiology of prostate cancer (3) (4) (5) (6) (7) (8) . Allelotyping studies such as that of Kunimi et al. (4) in prostate adenocarcinoma indicate candidate regions to include chromosome 8p(50-65%), 10p(55%), 10q(30%), 16q(55-60%), and 18q(43%) (4) . High-frequency loss of heterozygosity and homozygous deletion have been
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observed within chromosome 8p22 at the MSR locus in a prostate tumor (9) . Recently, a candidate tumor suppressor gene MXIJ was identified within 10q24 (10) . Mutation of the MXIJ gene, a negative regulator of the MYC oncoprotein, was found in 4 of 10 primary prostate tumors examined (10) .
Cytogenetic analyses of human prostatic adenocarcinoma have also implicated nonrandom aberrations of several different human chromosomes. A recent study by Lundgren et al. (11) indicated consistent aberrations of chromosomes 1, 7, 8, and 10. Breakpoints were identified at 7q22 and 10q24. The cumulative findings of cytogenetic analysis and allele loss studies suggest a consistent association with genetic loci on a subset of human chromosomes, the most consistent correlations being with chromosomes 8 and 10 and prostate carcinoma.
For our experiments, a functional genetic approach was taken to identify tumor suppressor loci involved in prostate cancer. Previous studies have shown that it is possible to complement the genetic defect in particular human cancers, which show high-frequency allele loss on a defined chromosome, by the microcell fusion (12, 13) of a normal copy of that chromosome containing a putative tumor suppressor gene (14) (15) (16) (17) (18) (19) (20) (21) . We report that the introduction of human chromosome 10 or a subchromosomal fragment of 10 (encompassing lOpter-qll) into a prostate adenocarcinoma cell line resulted in a dramatic suppression of tumor formation following injection of hybrid clones into nude mice. Furthermore, we provide evidence that complemented hybrid clones undergo programmed cell death in vitro via a mechanism of apoptosis that does not require nuclear localization of p53. Induction of phagocytosis of apoptotic cells by neighboring prostate cells was observed in vitro, a process reminiscent of prostatic involution in response to androgen withdrawal (22, 23) .
MATERIALS AND METHODS
Cell Lines and Construction of Hybrids. The prostatic adenocarcinoma cell line PC-3 was established from the poorly differentiated adenocarcinoma from a vertebral body metastasis in a patient with hormone-insensitive prostate cancer (24 (13, 25) .
Characterization of Microcell Hybrid Clones. For chromosome painting, human chromosome 10-specific DNA from HA(10)A was amplified by PCR using inter-Alu primers (26) . Hybridization and detection was carried out as described (21) .
Tumorigenicity Assays. The PC-3H line and PC(10) series hybrids were injected at 5 x 106 cells into each of three 6-to 8-week-old athymic nude mice (Harlan). Injections were performed subcutaneously and tumor volumes were monitored biweekly using calipers as described (21) .
Apoptosis Assays. The DNA laddering protocol was that of Fernandez et al. (27) . Detection of DNA fragmentation in situ followed the procedure of Gavrieli et al. (28 (29) .
RESULTS

Construction and Characterization of Monochromosomal
Microcell Hybrid Clones. A subcloned line of the prostatic adenocarcinoma PC-3 was chosen as recipient for microcell fusion of human chromosome 10. PC-3H contained no intact copies of human chromosome 10; however, small fragments of chromosome 10 interspersed throughout the genome were apparent by chromosome painting using chromosome 10-specific DNA as a probe (Fig. 1A ). HA(10)A was used as a donor cell line for microcell fusion into PC-3H [PC (10) In total, PC-3H was injected into 12 mice. activation of a cell death program. In this regard, prostatic chromosome was secretory epithelial cells and androgen-dependent prostate om the explanted carcinomas undergo apoptosis in response to androgen depriwas dependent on vation (22, 23) . Furthermore, during disease progression most ne 10. These data prostate carcinomas become androgen independent and rehinchromosomelO 1 fractory to further therapeutic manipulations (30) . To test ancer.
whether genes on chromosome 10 could restore the cell death Used to Limit the pathway in PC-3H, three PC(10) clones and two fragmentiing a Functional containing clones PC(l0pter-qll) clones were expanded for in ocalize the tumor vitro apoptosis assays. As a control, a hybrid was also conmicrocell hybrid structed containing an intact neo-marked human chromosome 8 in the PC-3H background [PC (8) (Fig. 4 A and B) . Phagocytosis of apoptotic cells has been commonly observed in vivo, 2) . Growth conditions were in either 10% fetal bovine serum (odd-numbered lanes) or 0.1% fetal bovine serum (evennumbered lanes). Lanes M, size markers.
and it is thought to be an efficient clearing mechanism to rid the developing tissue of large numbers of dying cells (22, 23, 31, 32) . Electron microscopic analysis confirmed TUNEL studies and indicated apoptosis and phagocytosis in PC (10) and PC(lOp) series hybrids (data not shown). These data functionally define a genetic locus within human chromosome lOpter-ql 1 that directs the programmed cell death of prostatic carcinoma cell line PC-3H. Furthermore, results from these studies strongly suggest that one mechanism of PAClmediated tumor suppression could be by induction of apopto-A _ sis. Finally, by analyses of these defined microcell hybrids, we have shown that the cell death pathway can be functionally restored in prostatic adenocarcinoma.
Apoptosis in PC(10) Series Hybrids Is Independent of Nuclear Localization of p53 or Downregulation of BCL2. The protein product of the tumor suppressor gene p53 has been shown to have a major role in regulation of apoptosis in other systems (33) . Alterations in the p53 gene and aberrant expression of p53 protein have been associated with poorly differentiated, metastatic, androgen-independent prostatic tumors (34) (35) (36) (37) . For these reasons, hybrid clones were examined for changes in levels of p53 protein coincident with the introduction of the region lOpter-qll into PC-3H cells. Immunohistochemistry was carried out to detect p53 protein in the PC-3H and PC(10) hybrid clones. Cells were cultured in vitro using conditions similar to those used to detect DNA fragmentation and then incubated with a monoclonal antibody against p53 (DO1) and a secondary antibody conjugated to horseradish peroxidase. No detectable p53 protein was observed in PC-3H cells (Fig. 5A ) when cells were grown in 10% or 0.1% fetal bovine serum. However, clearly detectable p53 protein was observed in hybrids containing either the intact human chromosome 10 or the lOpter-qil region (Fig. 5 C and D) . These data suggest that either the transcription of p53 is upregulated or the p53 protein is stabilized in response to introduction of a genetic locus within chromosome 10. p53 protein, however, fails to localize to the nucleus in hybrid cells.
In addition to its role in induction of apoptosis, wild-type p53 seems to be required for induction of GI arrest in the mammalian cell cycle. Rapid induction of stable p53 protein following UV irradiation of cells has been documented and suggests that the p53 pathway is required as a checkpoint in G1 to prevent entry into S phase until UV-damaged DNA can be repaired (38) . To determine whether p53 in PC-3H cells is capable of nuclear localization, UV was used to induce up- another prostatic adenocarcinoma line, and early passage human fibroblasts were also irradiated under the same conditions. Six hours post-UV irradiation, p53 protein was detected in the nuclei of primary human fibroblasts and LNCaP cells as expected for wild-type p53 (data not shown); however, in PC-3H cells, p53 protein was highly expressed only in the cytoplasm (Fig. SB) . Thus, p53 protein in PC-3H cells is upregulated by introduction of chromosome 10, chromosome lOpter-ql 1, and presumably PAC]; however, the p53 protein localizes to the cytoplasm.
Apoptotic cell death in PC(10) and PC(lOp) hybrids could also be the result of PACl-directed downregulation of BCL2, a protooncogene that has been shown to rescue certain cell types from apoptotic death (34, 35) . Previous work has shown that BCL2 is not expressed in normal prostate secretory epithelial cells. However, BCL2 is highly expressed in relapsed, androgen-independent prostate cancers (30) . To contains an exon 5 mutation in p53 that would cause a frameshift in the amino acid sequence (39) . Sequence analysis in our laboratory has confirmed the exon 5 mutation in codon 138 in the subcloned line PC-3H. The frameshift mutation generates a premature stop codon in exon 5, well before the nuclear localization signal in exon 10 (A.M.K., unpublished results). The consequence of this mutation would then be a truncated p53 protein that localizes to the cytoplasm. We furthermore report upregulation of p53 protein in PC-3H in response to UV and following the introduction of PAC], although the p53 protein remains in the cytoplasm. One possible explanation for these results could be that p53 has a nontranscriptional activation-dependent role in apoptosis as proposed by Caelles and coworkers (40) , perhaps in a cytoplasmic signaling pathway. An alternative explanation is that the tumor suppression and apoptosis in PC-3H cells does not require wild-type p53. In this regard, previous work has shown that the programmed cell death of murine androgen-dependent prostatic glandular cells in vivo following androgen ablation does not require wild-type p53 (41) . However, the apoptosis observed in these in vivo studies was the result of growth factor withdrawal; the cell death phenotype in the PC(10) and PC(lOp) hybrids does not require an inducing agent. These results, then, taken together would suggest that the tumor suppressor locus within lOpter-qll mediates its effect on apoptosis either independently or upstream of p53. Supportive of these data is the finding that p53 mutations in prostate cancer have been found in the later stages of disease (35) (36) implicate specific chromosomal regions as sites for putative tumor suppressor loci, these studies point to multiple regions on different chromosomes that are potentially involved in prostate cancer. Microcell fusion of defined chromosomal regions can functionally define the region containing tumor suppressor genes important in the genesis of this cancer. In addition, these studies and others indicate that complemented microcell hybrid clones are valuable to gain insight into the phenotypic changes in vitro and in vivo that accompany the introduction of a single copy of the normal genetic locus.
Defined deletion microcell hybrids can be very useful as starting materials for the physical mapping of PAC1 and to determine whether subsequent deletions in PC hybrids allow separation of the phenotypes of tumor suppression and apoptosis or indicate single gene involvement. Such deletion hybrids should be extremely valuable in combination with functional assays to isolate candidate tumor suppressor genes involved in prostate cancer. 
